Increased L-DOPA-derived dopamine following selective MAO-A or -B inhibition in rat striatum depleted of dopaminergic and serotonergic innervation

British Journal of Pharmacology

Volumn 170, Issue 5, 2013, Pages 999-1013

  Sader Mazbar, O ^a   Loboda, Y ^a   Rabey, M J ^b   Finberg, John P M ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

6 hydroxydopamine; clorgyline; glial cells; L DOPA; medium spiny neurons; microdialysis; OCT 3; Parkinson's disease; rasagiline

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 5,7 DIHYDROXYTRYPTAMINE; AMINE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CLORGYLINE; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOVANILLIC ACID; LEVODOPA; ORGANIC CATION TRANSPORTER 3; OXIDOPAMINE; RASAGILINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; EXTRACELLULAR SPACE; GLIA; GLIOSIS; IMMUNOFLUORESCENCE; MALE; MEDIUM SPINY NEURON; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

6-HYDROXYDOPAMINE; CLORGYLINE; GLIAL CELLS; L-DOPA; MEDIUM SPINY NEURONS; MICRODIALYSIS; OCT-3; PARKINSON'S DISEASE; RASAGILINE;

5,7-DIHYDROXYTRYPTAMINE; ANIMALS; ANTIPARKINSON AGENTS; BASAL GANGLIA; CLORGYLINE; DOPAMINE; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; FLUORESCENT ANTIBODY TECHNIQUE; GLIAL FIBRILLARY ACIDIC PROTEIN; INDANS; LEVODOPA; MALE; MICRODIALYSIS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONERGIC NEURONS;

EID: 84885658544     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12349     Document Type: Article

References (51)

1. Agid Y, Javoy F, Youdim MB, (1973). Monoamine oxidase and aldehyde dehydrogenase activity in the striatum of rats after 6-hydroxydopamine lesion of the nigrostriatal pathway. Br J Pharmacol 48: 175-178.
2. Arai R, Horiike K, Hasegawa Y, (1998). Dopamine-degrading activity of monoamine oxidase is not detected by histochemistry in neurons of the substantia nigra pars compacta of the rat. Brain Res 812: 275-278.
3. Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW, (1990). Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55: 981-988.
4. Carlsson A, Fowler CJ, Magnusson T, Oreland L, Wiberg A, (1981). The activities of monoamine oxidase-A and -B, succinate dehydrogenase and acid phosphatase in the rat brain after hemitransection. Naunyn Schmiedebergs Arch Pharmacol 316: 51-55.
5. Carta M, Carlsson T, Kirik D, Bjorklund A, (2007). Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 130 (Pt 7): 1819-1833.
6. Cui M, Aras R, Christian WV, Rappold PM, Hatwar M, Panza J, et al. (2009). The organic cation transporter-3 is a pivotal modulator of neurodegeneration in the nigrostriatal dopaminergic pathway. Proc Natl Acad Sci U S A 106: 8043-8048.
7. Demarest KT, Smith DJ, Azzaro AJ, (1980). The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. J Pharmacol Exp Ther 215: 461-468.
8. Ekblom J, Jossan SS, Bergstrom M, Oreland L, Walum E, Aquilonius SM, (1993). Monoamine oxidase-B in astrocytes. Glia 8: 122-132.
9. Engel K, Wang J, (2005). Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Mol Pharmacol 68: 1397-1407.
10. Finberg JP, Youdim MB, (2002). Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 43: 1110-1118.
11. Finberg JP, Wang J, Goldstein DS, Kopin IJ, Bankiewicz KS, (1995). Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats. J Neurochem 65: 1213-1220.
12. Glezer S, Finberg JP, (2003). Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens. Eur J Pharmacol 472: 173-177.
13. Green AR, Youdim MB, (1975). Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol 55: 415-422.
14. Hall FS, Devries AC, Fong GW, Huang S, Pert A, (1999). Effects of 5,7-dihydroxytryptamine depletion of tissue serotonin levels on extracellular serotonin in the striatum assessed with in vivo microdialysis: relationship to behavior. Synapse 33: 16-25.
15. Hayer-Zillgen M, Bruss M, Bonisch H, (2002). Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 136: 829-836.
16. Hida T, Hasegawa Y, Arai R, (1999). Histochemical study of dopamine-degrading monoamine oxidase activity in dopaminergic neurons of rat brain. Brain Res 842: 491-495.
17. Inazu M, Takeda H, Matsumiya T, (2003). Functional expression of the norepinephrine transporter in cultured rat astrocytes. J Neurochem 84: 136-144.
18. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. J Gene Med 12: 561-563.
19. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG, (2012). Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthritis Cartilage 20: 256-260.
20. Konradi C, Svoma E, Jellinger K, Riederer P, Denney R, Thibault J, (1988). Topographic immunocytochemical mapping of monoamine oxidase-A, monoamine oxidase-B and tyrosine hydroxylase in human post mortem brain stem. Neuroscience 26: 791-802.
21. Lamensdorf I, Youdim MB, Finberg JP, (1996). Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J Neurochem 67: 1532-1539.
22. Levitt P, Pintar JE, Breakefield XO, (1982). Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci U S A 79: 6385-6389.
23. Lopez-Real A, Rodriguez-Pallares J, Guerra MJ, Labandeira-Garcia JL, (2003). Localization and functional significance of striatal neurons immunoreactive to aromatic L-amino acid decarboxylase or tyrosine hydroxylase in rat Parkinsonian models. Brain Res 969: 135-146.
24. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ, (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275.
25. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
26. Maeda T, Kannari K, Shen H, Arai A, Tomiyama M, Matsunaga M, et al. (2003). Rapid induction of serotonergic hyperinnervation in the adult rat striatum with extensive dopaminergic denervation. Neurosci Lett 343: 17-20.
27. Miller DW, Abercrombie ED, (1999). Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine-treated rats. J Neurochem 72: 1516-1522.
28. Mura A, Jackson D, Manley MS, Young SJ, Groves PM, (1995). Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res 704: 51-60.
29. Navailles S, Bioulac B, Gross C, De Deurwaerdere P, (2010). Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 38: 136-143.
30. Nomura T, Yabe T, Rosenthal ES, Krzan M, Schwartz JP, (2000). PSA-NCAM distinguishes reactive astrocytes in 6-OHDA-lesioned substantia nigra from those in the striatal terminal fields. J Neurosci Res 61: 588-596.
31. O'Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF, (1983). The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322: 198-202.
32. O'Carroll AM, Tipton KF, Sullivan JP, Fowler CJ, Ross SB, (1987). Intra- and extra-neuronal deamination of dopamine and noradrenaline by the two forms of human brain monoamine oxidase. Implications for the neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Biog Amines 4: 165-178.
33. Otsuka S, Kobayashi Y, (1964). Radioisotopic assay for monoamine oxidase determinations in human plasma. Biochem Pharmacol 13: 995-1006.
34. Parkinson Study Group (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 62: 241-248.
35. Paterson IA, Juorio AV, Berry MD, Zhu MY, (1991). Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum. J Pharmacol Exp Ther 258: 1019-1026.
36. Paxinos G, Watson C, (1982). The Rat Brain in Stereotaxic Coordinates. Academic Press: Sydney.
37. Rodrigues RW, Gomide VC, Chadi G, (2001). Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine. Int J Neurosci 109: 91-126.
38. Scarr E, Wingerchuk DM, Juorio AV, Paterson IA, (1994). The effects of monoamine oxidase B inhibition on dopamine metabolism in rats with nigro-striatal lesions. Neurochem Res 19: 153-159.
39. Schwarting RK, Huston JP, (1996). The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50: 275-331.
40. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M, (1999). Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10: 631-634.
41. Tashiro Y, Kaneko T, Sugimoto T, Nagatsu I, Kikuchi H, Mizuno N, (1989). Striatal neurons with aromatic L-amino acid decarboxylase-like immunoreactivity in the rat. Neurosci Lett 100: 29-34.
42. Van der Krogt JA, Koot-Gronsveld E, Van den Berg CJ, (1983). Localization of rat striatal monoamine oxidase activities towards dopamine, serotonin and kynuramine by gradient centrifugation and nigro-striatal lesions. Life Sci 33: 615-623.
43. Vialou V, Balasse L, Dumas S, Giros B, Gautron S, (2007). Neurochemical characterization of pathways expressing plasma membrane monoamine transporter in the rat brain. Neuroscience 144: 616-622.
44. Wachtel SR, Abercrombie ED, (1994). L-3,4-dihydroxyphenylalanine-induced dopamine release in the striatum of intact and 6-hydroxydopamine-treated rats: differential effects of monoamine oxidase A and B inhibitors. J Neurochem 63: 108-117.
45. Waldmeier PC, Delini-Stula A, Maitre L, (1976). Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn Schmiedebergs Arch Pharmacol 292: 9-14.
46. Waldmeier PC, Felner AE, Maitre L, (1981). Long term effects of selective MAO inhibitors on MAO activity and amine metabolism. In:, Youdim MB, Paykel ES, (eds). Monoamine Oxidase Inhibitors. Wiley: New York, pp. 87-102.
47. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW, (1985). Distinct monoamine oxidase A and B populations in primate brain. Science 230: 181-183.
48. Westlund KN, Krakower TJ, Kwan SW, Abell CW, (1993). Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res 612: 221-230.
49. Willoughby J, Glover V, Sandler M, (1988). Histochemical localisation of monoamine oxidase A and B in rat brain. J Neural Transm 74: 29-42.
50. Yamada H, Aimi Y, Nagatsu I, Taki K, Kudo M, Arai R, (2007). Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats. Neurosci Res 59: 1-7.
51. Youdim MBH, Finberg JPM, (1983). Monoamine oxidase inhibitor antidepressants. In:, Grahame-Smith DG, Cowen PJ, (eds). Psychopharmacology, Vol. 1. Excerpta Medica: Amsterdam, pp. 38-70.